The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,900 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2014.
In addition, a comprehensive appendix of all clinical stage deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 includes:
Trends in clinical stage dealmaking in the biopharma industry since 2014
Analysis of clinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life clinical stage deals
Access to over 2,900 clinical stage deals
The leading clinical stage deals by value since 2014
Most active clinical stage dealmakers since 2014
The leading clinical stage partnering resources
In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021, the available contracts are listed by:
Stage of development at signing
Specific therapy target
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Why do companies partner clinical stage compounds? 2.1. Introduction 2.2. The role of clinical stage partnering 2.2.1. In-licensing at clinical stage 2.2.2. Out-licensing at clinical stage 2.3. Difference between phase I, II and III stage deals 2.4. Reasons for entering into clinical stage partnering deals 2.4.1. Licensors reasons for entering clinical stage deals 2.4.2. Licensees reasons for entering clinical stage deals 2.5. The future of clinical stage partnering deals
Chapter 3 - Clinical stage deal strategies and structure 3.1. Introduction 3.2. At what stage do companies partner? 3.2.1. Partnering early in pharmaceutical/biotech 188.8.131.52. Discovery and preclinical stage partnering case studies 184.108.40.206.a. Case study: LEO Pharma - 4SC 220.127.116.11.b. Case study: Heptares Therapeutics - Cubist 18.104.22.168.c. Case study: Incyte - Agenus Bio 22.214.171.124.d. Case study: Janssen Pharmaceutical - Evotec 3.2.2. Partnering later in pharmaceutical/biotech 126.96.36.199. Clinical stage partnering case studies 188.8.131.52.a. Case study: Servier - GeNeuro 184.108.40.206.b. Case study: Teva - Xenon Pharmaceuticals 220.127.116.11.c. Case study: AstraZeneca - Ardelyx 18.104.22.168.d. Case study: Baxter - Onconova Therapeutics 3.3. Early and later stage partnering - a risk/cost comparison 3.4. What do companies spend on clinical stage partnering? 3.5. Pure versus multi-component partnering deals 3.6. Pure licensing agreement structure 3.6.1. Example pure licensing agreements 3.6.1.a. Case study : Argos Therapeutics - Medinet 3.6.1.b. Case study : Pfizer - GlycoMimetics 3.7. Multicomponent clinical stage partnering agreements 3.7.1. Example multicomponent clinical stage clauses 3.7.1.a. Case study: Gilead Sciences - GlobeImmune
Chapter 5 - Trends in clinical stage deal making 5.1. Introduction 5.2. Clinical stage partnering over the years 5.2.1. Trends in phase I deals since 2014 22.214.171.124. Attributes of phase I deals 5.2.2. Trends in phase II deals since 2014 126.96.36.199. Attributes of phase II deals 5.2.3. Trends in phase III deals since 2014 188.8.131.52. Attributes of phase III deals 5.3. Clinical stage partnering by deal type 5.4. Clinical stage partnering by disease type 5.5. Partnering by clinical stage technology type 5.6. Clinical stage partnering by most active company since 2014
Chapter 6 - Payment terms for clinical stage partnering 6.1. Introduction 6.2. Guidelines for clinical stage payment terms 6.2.1. Upfront payments 6.2.2. Milestone payments 6.2.3. Royalty payments 6.3. Clinical stage payment terms - deal data analysis 6.3.1. Public data 6.3.2. Survey data 6.4. Payment terms analysis 6.4.1. Clinical stage partnering headline values 6.4.2. Clinical stage deal upfront payments 6.4.3. Clinical stage deal milestone payments 6.4.4. Clinical stage royalty rates 6.5 Clinical stage median financials 6.5.1. Clinical stage headline value 6.5.2. Clinical stage upfront value 6.5.3. Clinical stage milestone value 6.5.4. Clinical stage royalty value
Chapter 7 - Leading clinical stage deals 7.1. Introduction 7.2. Top clinical stage deals by value
Chapter 8 - Top 25 most active clinical stage dealmakers 8.1. Introduction 8.2. Top 25 most active clinical stage dealmakers
Chapter 9 - Clinical stage partnering contracts directory 9.1. Introduction 9.2. Clinical stage deals with contracts since 2014
Chapter 10 - Clinical stage deal making by development stage 10.1. Introduction 10.2. Deals by clinical stage Phase I Phase II Phase III Regulatory